APHEXDA® (motixafortide/BL-8040)
Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma
Key Facts
Indication
Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma
Phase
Approved
Status
Commercial
Company
About BioLineRx
BioLineRx is an Israeli biopharmaceutical company dedicated to identifying, in-licensing, and developing promising therapeutic candidates, primarily in oncology. Its strategic focus is on advancing motixafortide, which has demonstrated potential in multiple clinical settings, including as a stem cell mobilizer for autologous transplantation and as a combination therapy for metastatic pancreatic cancer. The company leverages a lean operational model to advance its pipeline through clinical development and strategic partnerships.
View full company profile